Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine

In this study we will compare 3 different anti-acids regimens and their effect on platelet function

Inclusion criteria

• Subject is at least 18 years old.
• Subject is willing to comply with pre-specified follow-up evaluation and can be contacted by telephone.
• Use of Clopidogrel (>=75mg) and Aspirin(>=75mg) for at least 1 month.

Exclusion criteria

• Known allergy to PPI of H2 blockers
• Known thrombocytopenia or thrombocytopathia
• Subject is currently enrolled in another investigational study of a new drug, biologic or device at the time of study screening. NOTE: Subjects who are participating in the long term follow-up phase of a previously investigational and now FDA-approved product are not excluded by this criterion.
• Subject with symptomatic heart failure of LVEF ≤ 25%
• Acute myocardial infarction within the past 30 days.
• No acute inflammatory event during the past month (e.g. infection, autoimmune or acute coronary event)
• Concurrent medical condition with a life expectancy of less than 12 months.
• Known severe renal failure (serum creatinine level >2.5 mg/dl).
• History of bleeding diathesis or coagulopathy or inability or unwillingness to receive blood transfusions.
• Evidence of active gastrointestinal bleeding or a history of such bleeding that is not known to have been treated and proven to have resolved.
• History of hepatitis (viral, ischemic or chemically-induced); clinical jaundice, history of cirrhosis.
• Patient treated with anticoagulant medication (Coumadin, LMWH)